GlycoMark® – Get Personalized Diabetes Info for Better Patient Care

We strive to combine the best testing in order to provide physicians with a more robust, detailed data set for diabetic patient care and treatment. As such, we include GlycoMark® as part of the Metabolic protocol. We feel it is important to provide patients with the information from GlycoMark®, as it is the only available test that specifically indicates recent hyperglycemic excursions (within 1 to 2 weeks prior). In addition to the ability of the test to identify recent hyperglycemic excursions, there are other pluses. For example, patients do not have to fast prior to the test, making it easier for them to schedule. It may be included as a monthly test to help monitor hyperglycemic episodes and glycemic control. Furthermore, it gives you actionable information to provide to your patients to improve patient care and treatment. The traditional A1C test reflects blood sugar levels for the past two or three months, providing an average of patient glucose levels. The A1c test may point to a higher average estimated glucose over a two to three month period but does not indicate the frequency or recentness of hyperglycemia or hypoglycemia. Using both A1c and Glycomark®, you are able to identify the impact of the care plan over the past two weeks. Information you receive from GlycoMark® can be used in the following ways:

  • It exposes more recent changes in glycemic control, allowing for appropriate changes in treatment programs or identifying patient non-adherence.
  • Hyperglycemic excursions will be identified, even if they are not contributing significantly to A1c.
  • Identify patients who may be showing “normal” under other testing methods as have significant glucose variability. This is especially important as we learn more about the impact of postprandial hyperglycemia as indicative of atherosclerosis than fasting glucose. Postprandial glucose may also be an independent contributor to both microvascular and macrovascular disease.
  • Like fructoseamine, Glycomark® is unaffected by hemoglobinopathies (A1c can be affected by hemoglobinopathies such as sickle cell trait).

Why Short-Term Measurements Matter

When patients’ glucose levels exceed 180 mg/dL for any period of time, the kidney cannot re-absorb all the glucose back into the blood. Therefore, the remaining glucose is excreted via the urine until the 1,5-AG returns to normal. The patient’s glucose level needs to remain below 180 mg/dL for approximately four weeks before the 1,5-AG returns to normal. By using Glycomark® to identify post prandial excursions or nocturnal excursions allows for more effective fingerstick glucose testing and potential changes to the diet or care plan. GlycoMark® divulges hyperglycemia, improving diabetes treatment. By ordering GlycoMark® testing for your diabetic patients, you tighten the glycemic control to minimize complications brought on by glycemic variability, including:

  • Vascular damage
  • Oxidative stress
  • Stroke
  • Dementia
  • Increased risk of death from cardiovascular causes

Glycomark® should not be used in patients with advanced liver or renal disease, pregnancy and use of SGLT2 inhibitors.   The test has not been cleared for Pediatrics or in persons who are not diagnosed with diabetes. Patients with diabetes need all the information available in order to make the best decisions, as do you. By managing glycemic variability, you have a better way to help prevent known health issues from diabetes. Don’t leave the management of hyperglycemic excursions to chance. Consider adding the GlycoMark® test to your regular diabetes treatment plan. It will give you and your patients better information for more thorough treatment plans and diabetes management.